Seegene and Shimadzu Agree to Join Multi-Pathogen Tests and Platform for Combined Analytics Solution

Seegene, Inc. and Shimadzu Corporation today announced a strategic partnership to combine Seegene's Seeplex^® multi-pathogen tests with Shimadzu's MultiNA ⁽¹⁾ analytical platform. Under terms of the deal, Shimadzu and Seegene will collaborate on integrating the Seeplex polymerase chain reaction-based tests with Shimadzu's MultiNA high-speed electrophoresis system to provide a highly sensitive, high-throughput multi-pathogen detection and analysis solution.

"This strategic agreement reinforces our plan to bring solutions, and not only products, to our customers," said Dr. Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene. "Shimadzu's MultiNA is outstanding in the market for electrophoresis analysis and a perfect match for the Seeplex family of multi-pathogen tests."

"Seegene's novel multi-pathogen detection test working with Shimadzu's next-generation electrophoresis systems creates an unparalleled screening platform for laboratories around the world," said Yoshiyuki Togawa, General Manager, Shimadzu. "Seeplex tests running on MultiNA is the fast, accurate and efficient way for laboratories to screen for the most rampant and debilitating pathogens infecting people around worldwide."

Shimadzu's MultiNA is a microchip electrophoresis system that quickly and easily performs DNA and RNA nucleic acid size confirmation and quantification. The system uses microchip technology to conduct fully automated high-speed electrophoresis separation, and fluorescence detection to perform high-sensitivity analysis.

Seeplex tests are based on a breakthrough multiplexing PCR technology capable of detecting multiple pathogens in a single tube. Seeplex-based tests deliver maximum specificity, reproducibility and sensitivity and can be applied to a broad range of molecular diagnostics, including human, animal, plant and microorganism. Currently, Seegene's Seeplex multi-pathogen detection tests offer labs worldwide simple, cost-effective and comprehensive screening for STDs, respiratory viruses, human papillomaviruses, sepsis and pneumonia.

(1) MultiNA is Research Use Only.